Insights on Investing in PODD – What Our Analysts Know

By Emilio Sanchez • Friday, September 01 09:47 • Permanent Link

Large-cap Health Care company Insulet has moved 0.7% so far today on a volume of 43,852, compared to its average of 842,590. In contrast, the S&P 500 index moved 0.0%.

Insulet trades -34.1% away from its average analyst target price of $292.94 per share. The 17 analysts following the stock have set target prices ranging from $208.0 to $360.0, and on average have given Insulet a rating of buy.

If you are considering an investment in PODD, you'll want to know the following:

Insulet's current price is 5785.2% above its Graham number of $3.28, which implies that at its current valuation it does not offer a margin of safety
Insulet has moved -24.0% over the last year, and the S&P 500 logged a change of 17.0%
Based on its trailing earnings per share of 0.95, Insulet has a trailing 12 month Price to Earnings (P/E) ratio of 203.2 while the S&P 500 average is 15.97
PODD has a forward P/E ratio of 86.2 based on its forward 12 month price to earnings (EPS) of $2.24 per share
The company has a price to earnings growth (PEG) ratio of 3.84 — a number near or below 1 signifying that Insulet is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 24.33 compared to its sector average of 4.16
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.
Based in Acton, the company has 2,600 full time employees and a market cap of $13.48 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.